Multi-condition nasal spray recalled
This column is provided by Ohio Northern University HealthWise Pharmacy.
All lots of Ferring Pharmaceuticals' multi-condition nasal spray are being recalled.
The problem? These lots have higher-than-specified amounts of desmopressin.
Higher amounts of desmopressin can lead to abnormally low levels of sodium in the blood. And very low levels of sodium in the blood can lead to dangerous health events, such as seizures, coma and even death.
This medication already has the potential to lead to serious and possibly life-threatening low levels of sodium in the blood. Now that these lots of nasal spray have been found to have higher-than-expected amounts of desmopressin, this risk is even higher.
Be sure to tell your health care provider about all of the medications you are taking, including prescription drugs, over-the-counter medications, vitamins, nutritional supplements and herbal products — especially loop diuretics ("water pills") like furosemide (Lasix).
Other medications to be on the lookout for include inhaled steroids like beclomethasone (Qnasl and Qvar) and oral steroids like dexamethasone.
This is not a complete list of potential drug interactions. Ask your doctor or pharmacist for more information.
The recalled nasal sprays are found under the following names:
DDAVP Nasal Spray 10 mcg/0.1mL
Desmopressin Acetate Nasal Spray 10 mcg/0.1mL
STIMATE Nasal Spray 1.5 mg/mL
The manufacturer said it had not noted an increase in adverse event reports tied to higher-than-normal levels of desmopressin. One non-fatal adverse event tied to these sprays had been reported.
Both DDAVP Nasal Spray and Desmopressin Acetate Nasal Spray are approved for the following: To control the symptoms of a certain type of diabetes insipidus, and to control excessive thirst and the passage of an abnormally large amount of urine that may occur after a head injury or after certain types of surgery
Stimate Nasal Spray is approved to stop some types of bleeding in people with hemophilia (when blood does not clot normally) and von Willebrand disease, a bleeding disorder, with certain blood levels.
If you experience an adverse reaction with the use of these products, you are encouraged to report it to the FDA's MedWatch Adverse Event Reporting program
Stories Posted This Week
Monday, October 19, 2026
- Jess Express Travel is the Icon's newest advertiser
- Gatchel 7th in girls, Pirates 4th at NWC cross country meet
- Veterans invited to Pandora-Gilboa banquet, November 10
- October 19 Bluffton Schools athletics lineup, streaming
- Wearable sculptures featured in exhibit On Soft Ground
- Historic depot rentals offered for meetings and parties
Sunday, October 18, 2026
Saturday, October 17, 2026
Friday, October 16, 2026
- Production offers a modern take on the story of St. Clare of Assisi
- Bluffton volleyball edged in 5 by Van Buren
- Pirate girls soccer tie O-G
- Bluffton Council recap: Officers honored for 25 years of service
- Bluffton Clean Up teams up with Troop 3256 Cub Scouts
- Ada FFA: Feeding the Farmers
- Nov. 7 Fall Community Day at Bluffton University
- Quarry Farm Nature Preserve news for Fall 2026
Thursday, October 15, 2026
- DeWine announces $200M Rural Health Transformation program award
- Herb program with Marge Lafollette, Oct. 15
- Prairie seeding activity at Bluffton University, October 24
- Food for thought: Choline for the brain
- Results for 5K on October 2, Bluffton University Homecoming event
- 15 minutes with Sherry Miller, senior center activities coordinator